FXS01 / Lysogene - LARVOL DELTA

Lysogene reports full year 2019 financial results and provides operational update (Businesswire) - "X Fragile program: Lysogene is engaged in a discovery collaboration with the lab of Hervé Moine at the IGBMC Strasbourg and SATT Conectus. The aim of the collaboration is to explore the therapeutic potential in fragile X syndrome of an AAV vector carrying a variant of diacylglycerol kinase kappa. Preclinical proof of concept studies in a mouse model of FXS are progressing as planned, with first results expected by the end of this year."

Preclinical • Fragile X Syndrome • Genetic Disorders